Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.

MLA

Morgenstern, Yael, et al. “Dose-Adjusted EPOCH-R Is Not Superior to Sequential R-CHOP/R-ICE as a Frontline Treatment for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Bi-Center Retrospective Study.” Cancer Medicine, vol. 10, no. 24, Dec. 2021, pp. 8866–75. EBSCOhost, https://doi.org/10.1002/cam4.4387.

APA

Morgenstern, Y., Aumann, S., Goldschmidt, N., Gatt, M. E., Nachmias, B., & Horowitz, N. A. (2021). Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study. Cancer Medicine, 10(24), 8866–8875. https://doi.org/10.1002/cam4.4387

Chicago

Morgenstern, Yael, Shlomzion Aumann, Neta Goldschmidt, Moshe E Gatt, Boaz Nachmias, and Netanel A Horowitz. 2021. “Dose-Adjusted EPOCH-R Is Not Superior to Sequential R-CHOP/R-ICE as a Frontline Treatment for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Bi-Center Retrospective Study.” Cancer Medicine 10 (24): 8866–75. doi:10.1002/cam4.4387.